Evidence map›Paper›PMID 38889227›Full record

ReviewScience signaling2024

Pin1-catalyzed conformational regulation after phosphorylation: A distinct checkpoint in cell signaling and drug discovery.

Kun Ping Lu, Xiao Zhen Zhou

Abstract readReview
In one paragraph

Review in Science signaling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kun Ping LuDepartments of Biochemistry and Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON N6G 2V4, Canada.ORCID 0000-0002-0734-1567
Xiao Zhen ZhouDepartments of Biochemistry and Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON N6G 2V4, Canada.ORCID 0009-0002-7849-2116

Funding

Development of Therapeutic Antibody for Traumatic Brain InjuryU01NS096835 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ZEIDEL, MARK L. · 2017 to 2021
$5.1M
Role of Tau Conformations in Vascular Contribution to Cognitive Impairment and DementiaR01AG055559 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LO, ENG H., SHEHADAH, AMJAD · 2017 to 2021
$3.4M
Development of selective Pin1 inhibitors to target a common oncogenic mechanismR01CA205153 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GRAY, NATHANAEL SCHIANDER, WULF, GERBURG M · 2017 to 2021
$3.3M
NCI NIH HHS R01 CA205153NIA NIH HHS R01 AG055559NINDS NIH HHS U01 NS096835
6 · The paper itself

Abstract

Protein phosphorylation is one of the most common mechanisms regulating cellular signaling pathways, and many kinases and phosphatases are proven drug targets. Upon phosphorylation, protein functions can be further regulated by the distinct isomerase Pin1 through cis-trans isomerization. Numerous protein targets and many important roles have now been elucidated for Pin1. However, no tools are available to detect or target cis and trans conformation events in cells. The development of Pin1 inhibitors and stereo- and phospho-specific antibodies has revealed that cis and trans conformations have distinct and often opposing cellular functions. Aberrant conformational changes due to the dysregulation of Pin1 can drive pathogenesis but can be effectively targeted in age-related diseases, including cancers and neurodegenerative disorders. Here, we review advances in understanding the roles of Pin1 signaling in health and disease and highlight conformational regulation as a distinct signal transduction checkpoint in disease development and treatment.

Indexed as

Drug DiscoveryNIMA-Interacting Peptidylprolyl IsomeraseProtein ConformationSignal TransductionAnimalsHumansNeoplasmsPhosphorylationNIMA-Interacting Peptidylprolyl IsomerasePIN1 protein, human

Identifiers

PMID38889227
PMCPMC11409840

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.